Abstract: This article enumerates the latest updates on clinical trials in triple-negative breast cancer (TNBC) in surgery, radiation, chemotherapy, targeted therapy and immunotherapy. Breast-conserving surgery and sentinel lymph node biopsy have become current trends in early-stage breast cancer, and breast reconstruction can significantly improve patients' quality life and mental health after mastectomy. The progress in radiotherapy includes regional lymph node radiation, intraoperative radiotherapy, hypofractionated radiation, and accelerated partial breast irradiation. In addition, olaparib, sacituzumab govitecan, halaven, utidelone, and Pembrolizumab have been applied in the treatment of TNBC, with promising efficacy and acceptable safety profiles. In the future, a better understanding of mechanisms involved in tumorigenesis, accompanied by individualized treatment, would improve the prognosis and life quality of patients with TNBC.